| Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease G Bianchini, JM Balko, IA Mayer, ME Sanders, L Gianni Nature reviews Clinical oncology 13 (11), 674-690, 2016 | 3194 | 2016 |
| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 2874 | 2018 |
| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 2465 | 2016 |
| Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data F Finotello, C Mayer, C Plattner, G Laschober, D Rieder, H Hackl, ... Genome medicine 11 (1), 34, 2019 | 1431 | 2019 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study JE Salem, A Manouchehri, M Moey, B Lebrun-Vignes, L Bastarache, ... The Lancet Oncology 19 (12), 1579-1589, 2018 | 1242 | 2018 |
| Immune-checkpoint inhibitors: long-term implications of toxicity DB Johnson, CA Nebhan, JJ Moslehi, JM Balko Nature Reviews Clinical Oncology 19 (4), 254-267, 2022 | 1002 | 2022 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 904 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 800 | 2017 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 792 | 2014 |
| TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer NE Bhola, JM Balko, TC Dugger, MG Kuba, V Sánchez, M Sanders, ... The Journal of clinical investigation 123 (3), 1348-1358, 2013 | 710 | 2013 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 694 | 2017 |
| Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy D Shae, KW Becker, P Christov, DS Yun, AKR Lytton-Jean, S Sevimli, ... Nature nanotechnology 14 (3), 269-278, 2019 | 691 | 2019 |
| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 662 | 2016 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 604 | 2016 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 588 | 2014 |
| Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer TW Miller, JM Balko, CL Arteaga Journal of clinical oncology 29 (33), 4452-4461, 2011 | 528 | 2011 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 521 | 2016 |
| Biological consequences of MHC-II expression by tumor cells in cancer ML Axelrod, RS Cook, DB Johnson, JM Balko Clinical cancer research 25 (8), 2392-2402, 2019 | 516 | 2019 |
| PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors BD Lehmann, JA Bauer, JM Schafer, CS Pendleton, L Tang, KC Johnson, ... Breast Cancer Research 16 (4), 406, 2014 | 420 | 2014 |
| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 397 | 2019 |
Douglas B JohnsonProfessor of Medicine, Vanderbilt University Medical CenterVerified email at vumc.org
